Covid-19 roundup: Controversy around colchicine percolates after study failure; AstraZeneca's meeting with EU was 'constructive,' but didn't solve much
A group of researchers at the Montreal Heart Institute has spelled out what they had called positive results suggesting that colchicine, an inexpensive oral anti-inflammatory drug commonly used to treat gout, could prevent Covid-19 complications in newly diagnosed patients.
The study failed its primary endpoint. But the latest scientific debate around treatments for the coronavirus is just beginning to brew.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.